Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | SOAT1 | P35610 | 3/20 | 0.56 |
| ▸ | SOAT2 | O75908 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10948543 | 0.90 | SMN1; SMN2 (0.82) | SMN1; SMN2KMT2AMEN1TDP1SOAT1 | |
| SCHEMBL9843936 | 0.87 | SMN1; SMN2 (0.77) | SMN1; SMN2KMT2AMEN1TDP1SOAT1 | |
| SCHEMBL7225295 | 0.86 | SMN1; SMN2 (0.75) | SMN1; SMN2KMT2AMEN1TDP1SOAT1 | |
| SCHEMBL9463095 | 0.84 | SMN1; SMN2 (0.72) | SMN1; SMN2KMT2AMEN1TDP1SOAT1 | |
| SCHEMBL9463141 | 0.82 | SMN1; SMN2 (0.70) | SMN1; SMN2KMT2AMEN1TDP1SOAT1 | |
| SCHEMBL2148218 | 0.82 | SMN1; SMN2 (0.70) | SMN1; SMN2KMT2AMEN1TDP1SOAT1 | |
| SCHEMBL3408925 | 0.82 | SMN1; SMN2 (0.70) | SMN1; SMN2KMT2AMEN1TDP1SOAT1 | |
| SCHEMBL6274717 | 0.81 | SMN1; SMN2 (0.68) | SMN1; SMN2SOAT1 | |
| SCHEMBL7769522 | 0.81 | SMN1; SMN2 (0.68) | SMN1; SMN2KMT2AMEN1LMNANLRP3 | |
| Benzene SCHEMBL9851028 | 0.81 | SMN1; SMN2 (0.68) | SMN1; SMN2KMT2AMEN1TDP1SOAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-6040898-A | — | — | None | — | — | JP | disclosed |
| JP-7316129-A | — | — | None | — | — | JP | disclosed |
| US-20240132479-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2024-04-25 | — | — | US | disclosed |
| WO-2022165198-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2022-08-04 | — | — | WO | disclosed |
| EP-2197851-B1 | DERIVATIVES OF N-PHENYLACETAMIDE AS INHIBITORS OF THE ENZYME SOAT1 FOR PHARMACEUTICAL AND COSMETIC USE | GALDERMA RES & DEV (FR) | 2013-10-23 | — | — | EP | disclosed |
| US-8513307-B2 | N-phenylacetamide inhibitors of the enzyme SOAT-1 and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-08-20 | — | — | US | disclosed |
| EP-2197850-B1 | DERIVATIVES OF N-PHENYLACETAMIDE, INHIBITORS OF THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM | GALDERMA RES & DEV (FR) | 2013-06-26 | — | — | EP | disclosed |
| US-8445523-B2 | Dioxo-imidazolidine derivatives, which inhibit the enzyme SOAT-1, and pharmaceutical and cosmetic compositions containing them | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-05-21 | — | — | US | disclosed |
| US-8420682-B2 | N-phenylacetamide derivatives, which inhibit the enzyme SOAT-1, and pharmaceutical and cosmetic compositions containing them | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-04-16 | — | — | US | disclosed |
| US-20130022644-A1 | NOVEL N-PHENYLACETAMIDE DERIVATIVES, WHICH INHIBIT THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM | GALDERMA RESEACH & DEVELOPMENT | 2013-01-24 | — | — | US | disclosed |
| EP-1354871-A1 | BIPHENYL DERIVATIVES | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2003-10-22 | — | — | EP | disclosed |
| EP-0874812-B1 | NOVEL 2,3,5-TRIMETHYL-4-HYDROXY ANILIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTICAL USE THEREOF | PF MEDICAMENT (FR) | 2000-04-05 | — | — | EP | disclosed |
| EP-0559898-B1 | ANILIDE DERIVATIVE | TAISHO PHARMACEUTICAL CO LTD (JP) | 1996-05-08 | — | — | EP | disclosed |
| US-5491152-A | Derivatives of cyclic ethers and sulfides for the treatment of atherosclerosis | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-02-13 | — | — | US | disclosed |
| US-5475130-A | A thio, sulfonyl, sulfoxidyl or sulfonate acetamide compound as enzyme inhibitor of acyl-coenzyme A cholesterol acyltransferase | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1995-12-12 | — | — | US | disclosed |
| JP-H07316129-A | PRODUCTION OF ALKYL THIOACETAMIDE | TAISHO PHARMACEUT CO LTD | 1995-12-05 | — | — | JP | disclosed |
| US-5416212-A | Antilipemic agents, enzyme inhibitors and anticholesterol agents | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1995-05-16 | — | — | US | disclosed |
| EP-0619312-A1 | ANILIDE DERIVATIVE | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1994-10-12 | — | — | EP | disclosed |
| JP-H0640898-A | ACAT-INHIBITING AGENT | TAISHO PHARMACEUT CO LTD | 1994-02-15 | — | — | JP | disclosed |
| EP-0559898-A1 | ANILIDE DERIVATIVE | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1993-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130022644-A1 | NOVEL N-PHENYLACETAMIDE DERIVATIVES, WHICH INHIBIT THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM | SOAT1, SOAT2, NAT1 | SMN1; SMN2 4076/4885KMT2A 238/4885MEN1 4542/4885 |
| US-20240132479-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | CUTA, DCXR, PLOD3 | SMN1; SMN2 560/4885KMT2A 2269/4885MEN1 2632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.